APA Alıntı

Rondon, E., & Venkataraman, R. (2005). Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels. BioMed Central.

Chicago Stili Alıntı

Rondon, Eliseo, ve Ramesh Venkataraman. Afelimomab Led to a Modest Mortality Benefit in Patients With Severe Sepsis and Elevated Interleukin-6 Levels. BioMed Central, 2005.

MLA Alıntı

Rondon, Eliseo, ve Ramesh Venkataraman. Afelimomab Led to a Modest Mortality Benefit in Patients With Severe Sepsis and Elevated Interleukin-6 Levels. BioMed Central, 2005.